- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study.
CMAJ Open. 2020 Jan-Mar;8(1):E191-E198
Death anxiety in patients with metastatic non-small cell lung cancer with and without brain metastases.
J Pain Symptom Manage. 2020 Mar 04;:
Cancer Med. 2020 Mar 02;:
Nat Chem Biol. 2020 Feb 24;:
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Cancer Treat Rev. 2020 Apr;85:101979
Lancet Oncol. 2020 Mar;21(3):322-324
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
J Clin Oncol. 2020 Jan 28;:JCO1903022
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.
Lancet Respir Med. 2020 Jan 15;:
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
Cancer. 2020 Apr 01;126(7):1550-1558
Cancer. 2020 Apr 01;126(7):1530-1540
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group